Eggebrecht Lisa, Bauerfeind Anja, Boehnke Tanja, Rizzo Manuel, Hagemann Christine, Lange Jens, Viet Mareike, Pauls Karl, von Stockum Sophia, Klinghardt Moritz, Heinemann Klaas
ZEG - Berlin Center for Epidemiology and Health Research, Invalidenstr. 115, 10115, Berlin, Germany.
Contracept Reprod Med. 2025 Mar 14;10(1):20. doi: 10.1186/s40834-025-00353-8.
The European Active Surveillance Study of LCS12 (EURAS-LCS12) investigates effectiveness and safety of intrauterine devices (IUDs) in routine clinical practice. Here, we aim to characterise the general population of IUD users across Europe recorded in a real-world setting.
EURAS-LCS12 is a prospective, non-interventional cohort study in ten European countries, that started in 2014. All types of approved IUDs were enrolled: levonorgestrel (LNG)-IUS 8 (LNG release rate ~ 8 µg/day); LNG-IUS 12 (LNG release rate ~ 12 µg/day; LNG-IUS 20 (LNG release rate ~ 20 µg/day; ); copper IUDs and other hormonal IUDs (OHIUD). A great variety of baseline characteristics and endpoints are assessed in patient-reported questionnaires. The follow-up duration aligns with the intended maximum duration of use of 3 to 5 years, depending on the respective IUD.
Currently, 97,187 users are enrolled in the study, of whom the vast majority uses IUDs for contraceptive purposes (96.3%), and roughly two thirds are first-time IUD users (64.1%). Heavy menstrual bleeding (HMB) was reported as the second most common reason for IUD use but with apparent variations between devices and countries. Mean age of LNG-IUD 8 users was about 9 years lower compared with LNG-IUD 20 (26.2 vs. 34.6 years). Greatest differences in the proportion of gravid and parous women were observed between LNG-IUS 8 and OHIUD users (gravid: 38.6% vs. 89.8%; para: 30.6% vs. 88.0%).
With more than 97,000 IUD users, EURAS-LCS12 is one of the largest contemporary studies focusing on IUD usage and provides a substantial source of real-world data. IUD prescription patterns appear in line with assumptions that high-dose LNG-IUDs with longer approved durations of use are predominantly prescribed among older, gravid women, who may have completed their family planning, as opposed to younger nulligravidae. Overall, the study is a great source to depict which IUD type fits women with certain characteristics and needs at a certain time of life.
NCT02146950.
欧洲宫内节育器(IUD)主动监测研究(EURAS-LCS12)旨在调查宫内节育器在常规临床实践中的有效性和安全性。在此,我们旨在描述在真实环境中记录的欧洲宫内节育器使用者的总体情况。
EURAS-LCS12是一项于2014年在10个欧洲国家开展的前瞻性、非干预性队列研究。纳入了所有类型的获批宫内节育器:左炔诺孕酮(LNG)-IUS 8(LNG释放率约为8μg/天);LNG-IUS 12(LNG释放率约为12μg/天);LNG-IUS 20(LNG释放率约为20μg/天);铜宫内节育器和其他激素宫内节育器(OHIUD)。通过患者报告问卷评估了各种各样的基线特征和终点指标。随访时间与相应宫内节育器预期的最长使用时间3至5年一致。
目前,该研究纳入了97187名使用者,其中绝大多数人使用宫内节育器是为了避孕(96.3%),约三分之二是首次使用宫内节育器的使用者(64.1%)。月经过多(HMB)被报告为使用宫内节育器的第二大常见原因,但不同器械和国家之间存在明显差异。LNG-IUD 8使用者的平均年龄比LNG-IUD 20使用者低约9岁(26.2岁对34.6岁)。在LNG-IUS 8和OHIUD使用者之间观察到妊娠和经产妇女比例的最大差异(妊娠:38.6%对89.8%;经产:30.6%对88.0%)。
EURAS-LCS12有超过97000名宫内节育器使用者,是关注宫内节育器使用情况的最大规模当代研究之一,并提供了大量真实世界数据来源。宫内节育器的处方模式似乎符合以下假设:获批使用期限较长的高剂量LNG宫内节育器主要开给年龄较大、已妊娠的妇女,她们可能已完成计划生育,而不是年轻的未孕妇女。总体而言,该研究是描绘哪种宫内节育器类型适合特定年龄段具有某些特征和需求的女性的重要数据来源。
NCT02146950。